Cardinal Health Stock Drops 7% Amid Acquisition and Q4 Earnings
ByAinvest
Tuesday, Aug 12, 2025 5:14 pm ET1min read
AENT--
Financial Highlights:
- Revenue: Q4 revenue was $60.2 billion, a 2% decrease from the previous year. Excluding the impact of a previously communicated customer contract expiration, revenue increased by 21% [1].
- Operating Earnings: GAAP operating earnings were $428 million, a 7% increase year-over-year (YoY). Non-GAAP operating earnings rose 19% to $719 million [1].
- EPS: GAAP diluted EPS was $1.00, while non-GAAP diluted EPS increased 13% to $2.08 [1].
- Acquisition: Cardinal Health announced the acquisition of Solaris Health, which will join the Specialty Alliance's Urology Alliance [1].
Stock Performance:
Cardinal Health's stock fell 7% after the announcement, with investors reacting to the acquisition's cost and the flat Q4 revenue. The company's shares traded at $120.50, down from $130.00 before the announcement.
Outlook:
Cardinal Health raised its 2026 non-GAAP EPS guidance to $9.30 to $9.50, a 13% to 15% increase from the previous guidance. The company expects revenue growth of 11% to 13% for the Pharmaceutical and Specialty Solutions segment, 2% to 4% for the Global Medical Products and Distribution segment, and 26% to 28% for the Other segment [1].
References:
[1] https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance
CAH--
SLSR--
Cardinal Health stock fell 7% after announcing a $1.9 billion acquisition of Solaris Health, a urology MSO, and reporting flat Q4 revenue at $60.2 billion. Non-GAAP net income rose 11% to $501 million, or $2.08 per share. The company raised its 2026 guidance, forecasting adjusted EPS of $9.30 to $9.50.
Cardinal Health (NYSE: CAH) reported its fourth quarter (Q4) and full year (FY) 2025 results, with stock falling 7% after the announcement of a $1.9 billion acquisition of Solaris Health, a leading urology medical services organization (MSO). The company's Q4 revenue was relatively flat at $60.2 billion, while non-GAAP net income rose 11% to $501 million, or $2.08 per share. Cardinal Health also raised its 2026 earnings per share (EPS) guidance to $9.30 to $9.50 [1].Financial Highlights:
- Revenue: Q4 revenue was $60.2 billion, a 2% decrease from the previous year. Excluding the impact of a previously communicated customer contract expiration, revenue increased by 21% [1].
- Operating Earnings: GAAP operating earnings were $428 million, a 7% increase year-over-year (YoY). Non-GAAP operating earnings rose 19% to $719 million [1].
- EPS: GAAP diluted EPS was $1.00, while non-GAAP diluted EPS increased 13% to $2.08 [1].
- Acquisition: Cardinal Health announced the acquisition of Solaris Health, which will join the Specialty Alliance's Urology Alliance [1].
Stock Performance:
Cardinal Health's stock fell 7% after the announcement, with investors reacting to the acquisition's cost and the flat Q4 revenue. The company's shares traded at $120.50, down from $130.00 before the announcement.
Outlook:
Cardinal Health raised its 2026 non-GAAP EPS guidance to $9.30 to $9.50, a 13% to 15% increase from the previous guidance. The company expects revenue growth of 11% to 13% for the Pharmaceutical and Specialty Solutions segment, 2% to 4% for the Global Medical Products and Distribution segment, and 26% to 28% for the Other segment [1].
References:
[1] https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet